Immuneering Corporation Payments to Acquire Marketable Securities
Immuneering Corporation (IMRX) reported Payments to Acquire Marketable Securities of $83.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- Immuneering Corporation payments to acquire marketable securities for the quarter ending 2026-06-30 was $11.99M.
- Immuneering Corporation payments to acquire marketable securities for the quarter ending 2026-03-31 was $71.99M.
- Immuneering Corporation payments to acquire marketable securities for the quarter ending 2025-12-31 was $88.60M.
- Immuneering Corporation payments to acquire marketable securities for the quarter ending 2025-09-30 was $0.00.
- Immuneering Corporation payments to acquire marketable securities for fiscal 2025 was $88.60M, a 1537.58% increase from fiscal 2024.
- Immuneering Corporation payments to acquire marketable securities for fiscal 2024 was $5.41M, a 87.89% decline from fiscal 2023.
- Immuneering Corporation payments to acquire marketable securities for fiscal 2023 was $44.66M, a 10.86% decline from fiscal 2022.
- Immuneering Corporation payments to acquire marketable securities for fiscal 2022 was $50.10M, a 33.75% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $83.98M 10-Q · filed 2026-08-05 | $172.58M derived: sum of 3 quarters · filed 2026-08-05 | $172.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $71.99M 10-Q · filed 2026-05-15 | $160.59M derived: sum of 2 quarters · filed 2026-05-15 | $160.59M derived: sum of 3 quarters · filed 2026-05-15 | $160.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $88.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $88.60M derived: sum of 2 quarters · filed 2026-03-06 | $88.60M derived: sum of 3 quarters · filed 2026-08-05 | $88.60M 10-K · filed 2026-03-06 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $5.41M 10-K · filed 2026-03-06 | ||
| 2024-09-30 | $5.41M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $15.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $44.66M derived: sum of 2 quarters · filed 2025-03-20 | $44.66M derived: sum of 3 quarters · filed 2025-03-20 | $44.66M 10-K · filed 2025-03-20 |
| 2023-09-30 | $28.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $28.91M derived: sum of 2 quarters · filed 2024-11-13 | $28.91M 10-Q · filed 2024-11-13 | $41.29M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $12.38M derived: sum of 3 quarters · filed 2024-03-01 | $32.12M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $12.38M derived: sum of 2 quarters · filed 2024-03-01 | $32.12M derived: sum of 3 quarters · filed 2024-03-01 | $42.12M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | $12.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $32.12M derived: sum of 2 quarters · filed 2024-03-01 | $42.12M derived: sum of 3 quarters · filed 2024-03-01 | $50.10M 10-K · filed 2024-03-01 |
| 2022-09-30 | $19.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $29.75M derived: sum of 2 quarters · filed 2023-11-09 | $37.73M 10-Q · filed 2023-11-09 | $60.59M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $10.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $17.99M 10-Q · filed 2023-08-03 | $40.85M derived: sum of 3 quarters · filed 2023-08-03 | |
| 2022-03-31 | $7.98M 10-Q · filed 2023-05-04 | $30.85M derived: sum of 2 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $22.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $75.63M 10-K · filed 2023-03-06 | ||
| 2021-09-30 | $52.76M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |